Common use of Important Safety Information Clause in Contracts

Important Safety Information. Rectiv is contraindicated in patients taking phosphodiesterase type 5 (PDE5) inhibitors (eg, sildenafil, vardenafil, and tadalafil), which can potentiate the hypotensive effect of nitrate, and in patients with severe anemia, increased intracranial pressure, or known hypersensitivity to nitroglycerin, other nitrates and nitrites, or any components of the ointment. The most common adverse reactions are headache and dizziness. For full US prescribing information please see: xxx.xxxxxxxxxx.xxx.xxx/xxxxxxxxxx_xxxx/xxxxx/0000/000000x000xxx.xxx

Important Safety Information. Rectiv RECTIV is contraindicated in patients taking phosphodiesterase type 5 (PDE5) inhibitors (ege.g., sildenafil, vardenafil, and tadalafil), which can potentiate the hypotensive effect of nitrate, and in patients with severe anemia, increased intracranial pressure, or known hypersensitivity to nitroglycerin, other nitrates and nitrites, or any components of the ointment. The most common adverse reactions are headache and dizziness. For full US U.S. prescribing information please see: xxx.xxxxxxxxxx.xxx.xxx/xxxxxxxxxx_xxxx/xxxxx/0000/000000x000xxx.xxxsee xxx.xxxxxxxxxx.xxx.xxx/xxxxxxxxxx_xxxx/xxxxx/0000/000000x000xxx.xxx (i) * Confidential treatment requested.